Merck Sharp + Dohme Corp.

Merck Sharpe & Dohme Corp.

Heidi Pixley

Jeffrey T Blue

Yan Li

Pingyu Zhong

Feng Dong

Rose M Cubbon

Holly A Hammond

Ayesha Sitlani

Kevin Caili Wang

Jon H Condra

Shilpa Pandit

Laurence B Peterson

Lynne Isopi

Denise K Nawrocki

Joseph C Santoro

Dana D Wood

Henryk Mach

Sonia M Gregory

Peizhi (Peter) Luo

Erin J Green-Trexler

Michael S Ryan

Sherrie-Ann P Martin

Akhilesh Bhambhani

Morrisa C Jones

Justin Stanbro

Timothy McCabe

Laura Orsatti

The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.

Formulations of dengue virus vaccine compositions

Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

1B20 PCSK9 antagonists

1D05 PCSK9 antagonists

Growing community of inventors

Glenside, PA, United States of America

Heidi Pixley